Dynacure
Latest round
- Series C
Last raised
- Apr 2020
Total raised
- $102M
Investors
- 9
About Dynacure
Based in Illkirch-Graffenstaden, France and founded in 2016, Dynacure SA operates as a biotechnology company that develops therapeutic drugs for the treatment of Myotubular and Centronuclear Myopathies (CNM). The company has 25 employees as of June 30, 2021 and was founded by its CEO, Stéphane van Rooijen, alongside Dr. Belinda Cowling. The company's product is a therapeutic solution that provides treatment for neuromuscular diseases, including myotubular and centronuclear myopathies or CNM, and other rare diseases. It develops DYN101, an antisense oligonucleotide, or ASO, that serves as a modifying medicine for the treatment of the majority of CNM patients. It reduces the expression of dynamin 2 or DNM2, a protein in the body that an excessive amount might affect the muscle cells of the human system. The company also offers DYN201, a discovery stage program that develops a potential treatment for a group of rare inherited neurodegenerative disorders called hereditary spastic paraplegias or HSP. The company's revenue is generated by the sales of its therapeutic solutions DYN101 and DYN201 to patients suffering from Myotubular and Centronuclear Myopathies (CNM) and hereditary spastic paraplegias or HSP. Dynacure SA plans to conduct a Phase 1/2 trial in Europe of DYN101 and expand its trial to sites in the US in 2H21.
Who invested in Dynacure
9 investors across 5 rounds
See all investors in Dynacure
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Dynacure
Who invested in Dynacure?
Dynacure has 9 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Dynacure raised?
Dynacure has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Dynacure last raise money?
Dynacure's most recent round on record is a Series C, in Apr 2020.
What does Dynacure do?
Based in Illkirch-Graffenstaden, France and founded in 2016, Dynacure SA operates as a biotechnology company that develops therapeutic drugs for the treatment of Myotubular and Centronuclear Myopathies (CNM).
Where is Dynacure headquartered?
Dynacure is headquartered in Illkirch-Graffenstaden, France.
Which VCs invest in companies like Dynacure?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Dynacure's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Dynacure? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.